Opinion

Video

Impact and Costs of Treatment Resistant Depression

Author(s):

Geoffrey Grammer, MD,Harman Deol, MD

Harman Deol, MD begins this series presenting an overview of treatment resistant depression (TRD), highlighting its prevalence along with its impact on patients and the healthcare system.

Related Videos
Parent Stress Reduces Over Time When Weaning Child Off Tube Feeding with Hide Okuno, MS
Akif Shameem, MD: Generalized Anxiety Disorder Linked to Longer Hospitals in Children with IBD
Jonathan Meyer, MD: Cognitive Gains, Dopamine-Free Schizophrenia Treatment with Xanomeline Trospium Chloride
Chelsie Monroe: Challenges Clinicians Should Consider When Prescribing Muscarinic Modulators for Schizophrenia
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Related Content
Hallucinogen-Related ER Visit Linked to Increased Schizophrenia Risk
November 14th 2024

Hallucinogen-Related ER Visit Linked to Increased Schizophrenia Risk

Chelsie Derman
Default thumbnail for Medical Ethics Unpacked
October 17th 2024

Introducing Medical Ethics Unpacked, with Dominic Sisti, PhD, and Steve Levine, MD

Steve Levine, MD Dominic Sisti, PhD
Emraclidine Fails to Significantly Reduce Schizophrenia Symptoms in Phase 2 EMPOWER Trials
November 11th 2024

Emraclidine Fails to Significantly Reduce Schizophrenia Symptoms in Phase 2 EMPOWER Trials

Chelsie Derman
The Physician Burnout Crisis, with Sue Padernacht, EDd, PCC
January 11th 2024

The Physician Burnout Crisis, with Sue Padernacht, EDd, PCC

Kevin Kunzmann
Phase 3 Data Shows Lumateperone Delays Schizophrenia Relapse Longer Than Placebo
November 6th 2024

Phase 3 Data Shows Lumateperone Delays Schizophrenia Relapse Longer Than Placebo

Chelsie Derman
Phase 3 Data Shows TEV-‘749 Injection Improves Social Function in Schizophrenia
November 6th 2024

Phase 3 Data Shows TEV-‘749 Injection Improves Social Function in Schizophrenia

Chelsie Derman
© 2024 MJH Life Sciences

All rights reserved.